Kevin Feeley sold $555k of WGS
CHIEF FINANCIAL OFFICER at GeneDx Holdings Corp.. 3,855 shares at an average of $143.87, traded Dec 16, 2025, filed Dec 18, 2025.
Score components
- +22RoleCFO
- +19Trade size$555k at market
- +10Share of holdings soldSold 31% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001944119-25-000021, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 16, 2025 | MOption exercise Class A Common Stock | +7,197 | $0.00 | $0 | 12,586 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -131 | $138.93 | $18k | 12,455 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -366 | $140.08 | $51k | 12,089 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -951 | $141.20 | $134k | 11,138 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -215 | $142.12 | $31k | 10,923 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -334 | $144.27 | $48k | 10,589 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -578 | $145.36 | $84k | 10,011 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -699 | $146.93 | $103k | 9,312 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -331 | $148.55 | $49k | 8,981 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -97 | $149.20 | $14k | 8,884 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -26 | $150.75 | $3,920 | 8,858 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -127 | $140.45 | $18k | 8,731 | Dec 18, 2025 |
| Dec 16, 2025 | MOption exercise Restricted Stock Unitderivative | -7,197 | $0.00 | $0 | 35,984 | Dec 18, 2025 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 53Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.6M 10,857 shares | -43% | |
| 32Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $202k 1,266 shares | -19% | |
| 47Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $580k 3,639 shares | -36% | |
| 29Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $61k 377 shares | -8% | |
| 68Notable | GeneDx Holdings Corp. | Joshua Ruch director | $6.1M 38,000 shares | -256% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.